logo
  

ObsEva Submits MAA To EMA For YSELTY For Treatment Of Women With Uterine Fibroids

ObsEva SA (OBSV) said that it has submitted a marketing authorization application to the European Medicines Agency or EMA for YSELTY or linzagolix 100mg and linzagolix 200mg for the management of heavy menstrual bleeding associated with uterine fibroids.

ObsEva expects that the EMA will notify the company in December 2020 regarding the outcome of its validation of the MAA to ensure all essential regulatory elements required for a scientific assessment are included in the application prior to the start of the procedure.

ObsEva expects to submit a new drug application to U.S. Food and Drug Administration in the first-half of 2021.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
After Disney World, retail giant Walmart Inc. (WMT) makes it mandatory for all its employees to wear mask on their facilities in the "high-risk" states where the Delta variant of Coronavirus has become menacing. The orders will be in effect immediately. The Center for Disease Control and Prevention... Generac Power Systems is recalling 325,735 units of Generac and DR 6500 Watt and 8000 Watt portable generators for potential risk of finger amputation and crushing hazards, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. These include 4,575 units sold in Canada. Omaha, Nebraska- based Greater Omaha Packing is recalling around 295,236 pounds of raw beef products citing the possible presence of E. coli O157:H7, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS said. The raw beef products intended for non-intact use were produced on July 13.
Follow RTT